Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 AML relapse after rituximab treatment for GvHD: crucial role for B cells in GvL responses.

Literature DB >> 27088384

AML relapse after rituximab treatment for GvHD: crucial role for B cells in GvL responses.

M A Gillissen^1,2, G de Jong^1,2, S E Levie¹, E Yasuda¹, A Q Bakker¹, L M Evers², S T Pals³, C Huisman², P M van Helden¹, H Spits¹, M D Hazenberg².

Abstract

Entities: Chemical Disease

Mesh：

Substances：
Rituximab

Year: 2016 PMID： 27088384 DOI： 10.1038/bmt.2016.90

Source DB: PubMed Journal: Bone Marrow Transplant ISSN： 0268-3369 Impact factor: 5.483

× No keyword cloud information.

19 in total

1. Generation of stable monoclonal antibody-producing B cell receptor-positive human memory B cells by genetic programming.

Authors: Mark J Kwakkenbos; Sean A Diehl; Etsuko Yasuda; Arjen Q Bakker; Caroline M M van Geelen; Michaël V Lukens; Grada M van Bleek; Myra N Widjojoatmodjo; Willy M J M Bogers; Henrik Mei; Andreas Radbruch; Ferenc A Scheeren; Hergen Spits; Tim Beaumont
Journal: Nat Med Date: 2009-12-20 Impact factor: 53.440

2. Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment: relationships with B cell depletion, circulating antibodies, and clinical relapse.

Authors: Geraldine Cambridge; William Stohl; Maria J Leandro; Thi-Sau Migone; David M Hilbert; Jonathan C W Edwards
Journal: Arthritis Rheum Date: 2006-03

3. A Randomized Phase II Crossover Study of Imatinib or Rituximab for Cutaneous Sclerosis after Hematopoietic Cell Transplantation.

Authors: Sally Arai; Joseph Pidala; Iskra Pusic; Xiaoyu Chai; Samantha Jaglowski; Nandita Khera; Jeanne Palmer; George L Chen; Madan H Jagasia; Sebastian A Mayer; William A Wood; Michael Green; Teresa S Hyun; Yoshihiro Inamoto; Barry E Storer; David B Miklos; Howard M Shulman; Paul J Martin; Stefanie Sarantopoulos; Stephanie J Lee; Mary E D Flowers
Journal: Clin Cancer Res Date: 2015-09-16 Impact factor: 12.531

Review 4. Efficacy of rituximab in the setting of steroid-refractory chronic graft-versus-host disease: a systematic review and meta-analysis.

Authors: Mohamed A Kharfan-Dabaja; Asmita R Mhaskar; Benjamin Djulbegovic; Corey Cutler; Mohamad Mohty; Ambuj Kumar
Journal: Biol Blood Marrow Transplant Date: 2009-06-10 Impact factor: 5.742

AML relapse after rituximab treatment for GvHD: crucial role for B cells in GvL responses.

1. Generation of stable monoclonal antibody-producing B cell receptor-positive human memory B cells by genetic programming.

2. Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment: relationships with B cell depletion, circulating antibodies, and clinical relapse.

3. A Randomized Phase II Crossover Study of Imatinib or Rituximab for Cutaneous Sclerosis after Hematopoietic Cell Transplantation.

Review 4. Efficacy of rituximab in the setting of steroid-refractory chronic graft-versus-host disease: a systematic review and meta-analysis.

5. Detection of a potent humoral response associated with immune-induced remission of chronic myelogenous leukemia.

Review 6. Effector and regulatory B cells: modulators of CD4+ T cell immunity.

Review 7. Allogeneic haematopoietic stem cell transplantation: individualized stem cell and immune therapy of cancer.

8. Relapse of preB-ALL after rituximab treatment for chronic graft versus host disease: implications for its use?

9. Antibodies specifically target AML antigen NuSAP1 after allogeneic bone marrow transplantation.

Review 10. Advances in graft-versus-host disease biology and therapy.

Review 1. Tumour-reactive B cells and antibody responses after allogeneic haematopoietic cell transplantation.

2. Survival of early posthematopoietic stem cell transplantation relapse of myeloid malignancies.